HBV, HCV
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases worldwide. The two viruses share same modes of transmission, coinfection is not uncommon, especially among high risk populations.
Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period? Jain et, al
Direct-acting antivirals (DAA) for hepatitis C virus (HCV) became available in 2014, but the role of mental health or substance use disorders (MH/SUD) on access to treatment is unknown. The objective of this study was to examine the extent and predictors of HCV treatment in the pre-DAA and post-DAA periods in four large, diverse health care settings in the United States.
Action plan for the health sector response to viral hepatitis in the WHO European Region
This very first Action plan for the health sector response to viral hepatitis in the WHO European Region has been developed through a truly inclusive consultative approach. It draws on the expertise of an advisory committee and has benefited from the input of Member States, major partners and civil society, including patient organizations which represent the people who live with viral hepatitis in Europe.
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review
A country-level, regional, and global estimates of coverage of NSP,
OST, HIV testing, ART, and condom programmes for PWID
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond
The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services
Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Zibbell et al.
These findings strongly suggest that the national increase in acute HCV infection is related to the country's opioid epidemic and associated increases in IDU.
Interim impact evaluation of the hepatitis C virus elimination program in Georgia
The Georgia HCV elimination program has accomplished an impressive scale up of treatment, which has already impacted on prevalence and incidence, and averted deaths due to HCV. However, extensive scale up is needed to achieve a 90% reduction in prevalence by 2020.
Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019 Accountability for the global health sector strategies, 2016–2021
WHO is accountable for reporting back to the World Health Assembly on progress in implementing the strategies based on data received from countries. This report assesses the mid-term progress in 2019 in implementing these global health sector strategies from 2016 to 2021.
Hepatitis C: New Models of Care for Drug Services
This collection of case studies was commissioned by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA contract CT.17.HEA.0088.1.0) to promote the dissemination of good implementation practices in the field of hepatitis C testing and care for people who inject drugs.
WHO Hepatitis C Fact Sheet
WHO fact sheet provides the most recent information about HCV prevention, treatment and testing
Treatment Action Group: Pipeline Report HCV Diagnostics
This report provides an overview of HCV diagnostic screening products and point of care testing developments worldwide.
